The Spanish drug industry association Farmaindustria and the Ministry of Health are in a coincidental alliance of concern over the level of drug costs generated by pensioners, who reportedly represent 74% of drug sales while standing at only 24% of the insured population. Drug spending generally has risen 130% in the past seven years and, with economies pending, Farmaindustria is concerned that they are not applied at its expense. It says that under existing agreements with the government, it has paid 65 billion pesetas ($516.6 million) in the last two years in various taxes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze